<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Metab Syndr Obes</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Metab Syndr Obes</journal-id><journal-id journal-id-type="publisher-id">Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</journal-id><journal-title-group><journal-title>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</journal-title></journal-title-group><issn pub-type="epub">1178-7007</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25834460</article-id><article-id pub-id-type="pmc">4358417</article-id><article-id pub-id-type="doi">10.2147/DMSO.S78623</article-id><article-id pub-id-type="publisher-id">dmso-8-147</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Daily intake of rosehip extract decreases abdominal visceral fat in preobese subjects: a randomized, double-blind, placebo-controlled clinical trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nagatomo</surname><given-names>Akifumi</given-names></name><xref ref-type="aff" rid="af1-dmso-8-147">1</xref><xref ref-type="corresp" rid="c1-dmso-8-147"></xref></contrib><contrib contrib-type="author"><name><surname>Nishida</surname><given-names>Norihisa</given-names></name><xref ref-type="aff" rid="af1-dmso-8-147">1</xref></contrib><contrib contrib-type="author"><name><surname>Fukuhara</surname><given-names>Ikuo</given-names></name><xref ref-type="aff" rid="af2-dmso-8-147">2</xref></contrib><contrib contrib-type="author"><name><surname>Noro</surname><given-names>Akira</given-names></name><xref ref-type="aff" rid="af3-dmso-8-147">3</xref></contrib><contrib contrib-type="author"><name><surname>Kozai</surname><given-names>Yoshimichi</given-names></name><xref ref-type="aff" rid="af3-dmso-8-147">3</xref></contrib><contrib contrib-type="author"><name><surname>Sato</surname><given-names>Hisao</given-names></name><xref ref-type="aff" rid="af3-dmso-8-147">3</xref></contrib><contrib contrib-type="author"><name><surname>Matsuura</surname><given-names>Yoichi</given-names></name><xref ref-type="aff" rid="af1-dmso-8-147">1</xref></contrib></contrib-group><aff id="af1-dmso-8-147"><label>1</label>Research and Development Division, Morishita Jintan Co, Ltd, Osaka, Japan</aff><aff id="af2-dmso-8-147"><label>2</label>Fukuhara Clinic, Hokkaido, Japan</aff><aff id="af3-dmso-8-147"><label>3</label>New Drug Research Center, Inc., Hokkaido, Japan</aff><author-notes><corresp id="c1-dmso-8-147">Correspondence: Akifumi Nagatomo, Research and Development Division, Morishita Jintan Co, Ltd, 2-11-1, Tsudayamate, Hirakata, Osaka 5730128, Japan, Tel +81 72 800 1044, Fax +81 72 800 2903, Email <email>a-nagatomo@jintan.co.jp</email></corresp></author-notes><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>06</day><month>3</month><year>2015</year></pub-date><volume>8</volume><fpage>147</fpage><lpage>156</lpage><permissions><copyright-statement>© 2015 Nagatomo et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License</copyright-statement><copyright-year>2015</copyright-year><license><license-p>The full terms of the License are available at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><sec><title><offsets xml_i="3956" xml_f="3966" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3977" xml_f="4387" txt_i="22" txt_f="432">Obesity has become a great problem all over the world. We repeatedly screened to find an effective food to treat obesity and discovered that rosehip extract shows potent anti-obesity effects. Investigations in mice have demonstrated that rosehip extract inhibits body weight gain and decreases visceral fat. Thus, the present study examined the effect of rosehip extract on human body fat in preobese subjects.</offsets></p></sec><sec><title><offsets xml_i="4409" xml_f="4416" txt_i="434" txt_f="441">Methods</offsets></title><p><offsets xml_i="4427" xml_f="4906" txt_i="442" txt_f="918">We conducted a 12-week, single-center, double-blind, randomized, placebo-controlled study of 32 subjects who had a body mass index of ≥25 but &lt;30. The subjects were assigned to two random groups, and they received one tablet of placebo or rosehip that contained 100 mg of rosehip extract once each day for 12 weeks with no dietary intervention. Abdominal fat area and body fat percent were measured as primary outcomes. The other outcomes were body weight and body mass index.</offsets></p></sec><sec><title><offsets xml_i="4928" xml_f="4935" txt_i="920" txt_f="927">Results</offsets></title><p><offsets xml_i="4946" xml_f="5127" txt_i="928" txt_f="1109">Abdominal total fat area, abdominal visceral fat area, body weight, and body mass index decreased significantly in the rosehip group at week 12 compared with their baseline levels (</offsets><italic><offsets xml_i="5135" xml_f="5136" txt_i="1109" txt_f="1110">P</offsets></italic><offsets xml_i="5145" xml_f="5577" txt_i="1110" txt_f="1539">&lt;0.01) after receiving the rosehip tablet intake, and the decreases in these parameters were significantly higher when compared with those in the placebo group. Additionally, body fat percent tended to decrease compared with the placebo group and their baseline level. Moreover, the abdominal subcutaneous fat area was significantly lower in the rosehip group than in the placebo group at week 12 after the initiation of intake (</offsets><italic><offsets xml_i="5585" xml_f="5586" txt_i="1539" txt_f="1540">P</offsets></italic><offsets xml_i="5595" xml_f="5742" txt_i="1540" txt_f="1684">&lt;0.05). In addition, there were no abnormalities, subjective symptoms, and findings that may indicate clinical problems during the study period.</offsets></p></sec><sec><title><offsets xml_i="5764" xml_f="5774" txt_i="1686" txt_f="1696">Conclusion</offsets></title><p><offsets xml_i="5785" xml_f="5889" txt_i="1697" txt_f="1801">These results suggest that rosehip extract may be a good candidate food material for preventing obesity.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>tiliroside</kwd><kwd>obesity</kwd><kwd>dietary supplement</kwd><kwd>randomized clinical trial</kwd><kwd><italic>Rosa canina</italic> L.</kwd><kwd>weight loss</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="6182" xml_f="6194" txt_i="1810" txt_f="1822">Introduction</offsets></title><p><offsets xml_i="6205" xml_f="6482" txt_i="1823" txt_f="2100">Obesity is one of the most important diseases and has become a global health problem. It is caused when a balance between energy intake and expenditure is lost and is characterized as a state of increased body weight by excessive lipid accumulation in the white adipose tissue.</offsets><xref rid="b1-dmso-8-147" ref-type="bibr"><offsets xml_i="6524" xml_f="6525" txt_i="2100" txt_f="2101">1</offsets></xref><offsets xml_i="6532" xml_f="6782" txt_i="2101" txt_f="2351"> Hypertrophied fat cells can increase a risk of type 2 diabetes associated with insulin resistance. Obesity can cause dysbolisms such as hyperlipidemia, hypertension, and arteriosclerosis, and these disorders can induce fatal cardiovascular diseases.</offsets><xref rid="b2-dmso-8-147" ref-type="bibr"><offsets xml_i="6824" xml_f="6825" txt_i="2351" txt_f="2352">2</offsets></xref><offsets xml_i="6832" xml_f="6981" txt_i="2352" txt_f="2501"> Therefore, the prevention and improvement of obesity, particularly decrease of visceral fat is important in the control of these metabolic diseases.</offsets></p><p><offsets xml_i="6988" xml_f="7350" txt_i="2502" txt_f="2864">Various functional foods or natural components have been recently developed for preventing or improving obesity as the alternative means of lifestyle improvement or medical treatment for obesity. As the result of our screening, we found that tiliroside, a major rosehip seed constituent, has fat metabolism acceleration and glucose clearance improvement effects.</offsets><xref rid="b3-dmso-8-147" ref-type="bibr"><offsets xml_i="7392" xml_f="7393" txt_i="2864" txt_f="2865">3</offsets></xref></p><p><offsets xml_i="7407" xml_f="7435" txt_i="2866" txt_f="2894">Rosehip, the whole fruit of </offsets><italic><offsets xml_i="7443" xml_f="7454" txt_i="2894" txt_f="2905">Rosa canina</offsets></italic><offsets xml_i="7463" xml_f="7694" txt_i="2905" txt_f="3136"> L. belonging to the family Rosaceae, is popular all over the world. In Europe and America, rosehip is processed widely into jam and juice, used as a vitamin C supplement, in cosmetics, and as a folklore drug in the form of tisane.</offsets><xref rid="b4-dmso-8-147" ref-type="bibr"><offsets xml_i="7736" xml_f="7737" txt_i="3136" txt_f="3137">4</offsets></xref><offsets xml_i="7744" xml_f="7745" txt_i="3137" txt_f="3138">,</offsets><xref rid="b5-dmso-8-147" ref-type="bibr"><offsets xml_i="7787" xml_f="7788" txt_i="3138" txt_f="3139">5</offsets></xref><offsets xml_i="7795" xml_f="7921" txt_i="3139" txt_f="3265"> The functional capacities of rosehip includes efficacy on diuresis, as a laxative, and as treatments for gout and rheumatism.</offsets><xref rid="b6-dmso-8-147" ref-type="bibr"><offsets xml_i="7963" xml_f="7964" txt_i="3265" txt_f="3266">6</offsets></xref><offsets xml_i="7971" xml_f="7972" txt_i="3266" txt_f="3267">,</offsets><xref rid="b7-dmso-8-147" ref-type="bibr"><offsets xml_i="8014" xml_f="8015" txt_i="3267" txt_f="3268">7</offsets></xref><offsets xml_i="8022" xml_f="8095" txt_i="3268" txt_f="3341"> There have also been reports of several effects including antioxidative,</offsets><xref rid="b8-dmso-8-147" ref-type="bibr"><offsets xml_i="8137" xml_f="8138" txt_i="3341" txt_f="3342">8</offsets></xref><offsets xml_i="8145" xml_f="8186" txt_i="3342" txt_f="3383"> anticold, and anti-inflammatory actions,</offsets><xref rid="b9-dmso-8-147" ref-type="bibr"><offsets xml_i="8228" xml_f="8229" txt_i="3383" txt_f="3384">9</offsets></xref><offsets xml_i="8236" xml_f="8362" txt_i="3384" txt_f="3510"> inhibitory effects on metabolism of arachidonic acid and formation of cyclooxygenase 1, cyclooxygenase 2, and leukotriene B4,</offsets><xref rid="b10-dmso-8-147" ref-type="bibr"><offsets xml_i="8405" xml_f="8407" txt_i="3510" txt_f="3512">10</offsets></xref><offsets xml_i="8414" xml_f="8514" txt_i="3512" txt_f="3612"> suppression of inflammation and cancer cell proliferation attributable to anticomplementary effect,</offsets><xref rid="b11-dmso-8-147" ref-type="bibr"><offsets xml_i="8557" xml_f="8559" txt_i="3612" txt_f="3614">11</offsets></xref><offsets xml_i="8566" xml_f="8636" txt_i="3614" txt_f="3684"> antibacterial action and suppression of experimental nephrolithiasis,</offsets><xref rid="b12-dmso-8-147" ref-type="bibr"><offsets xml_i="8679" xml_f="8681" txt_i="3684" txt_f="3686">12</offsets></xref><offsets xml_i="8688" xml_f="8719" txt_i="3686" txt_f="3717"> melanin production inhibition,</offsets><xref rid="b13-dmso-8-147" ref-type="bibr"><offsets xml_i="8762" xml_f="8764" txt_i="3717" txt_f="3719">13</offsets></xref><offsets xml_i="8771" xml_f="8840" txt_i="3719" txt_f="3788"> and antidiarrheal action using a methanol extract of rosehip leaves.</offsets><xref rid="b14-dmso-8-147" ref-type="bibr"><offsets xml_i="8883" xml_f="8885" txt_i="3788" txt_f="3790">14</offsets></xref><offsets xml_i="8892" xml_f="9002" txt_i="3790" txt_f="3900"> Large-scale clinical studies have confirmed the efficacy of rosehip in treating human knee joint arthropathy.</offsets><xref rid="b15-dmso-8-147" ref-type="bibr"><offsets xml_i="9045" xml_f="9047" txt_i="3900" txt_f="3902">15</offsets></xref></p><p><offsets xml_i="9061" xml_f="9142" txt_i="3903" txt_f="3984">It is well known that rosehip contains an abundance of vitamin C and polyphenols.</offsets><xref rid="b16-dmso-8-147" ref-type="bibr"><offsets xml_i="9185" xml_f="9187" txt_i="3984" txt_f="3986">16</offsets></xref><offsets xml_i="9194" xml_f="9353" txt_i="3986" txt_f="4145"> Especially, tiliroside, a major glycosidic flavonoid isolated from rosehip seed, has a variety of pharmacological activities, eg, an anticomplementary effect,</offsets><xref rid="b17-dmso-8-147" ref-type="bibr"><offsets xml_i="9396" xml_f="9398" txt_i="4145" txt_f="4147">17</offsets></xref><offsets xml_i="9405" xml_f="9434" txt_i="4147" txt_f="4176"> a hepatic protection action,</offsets><xref rid="b18-dmso-8-147" ref-type="bibr"><offsets xml_i="9477" xml_f="9479" txt_i="4176" txt_f="4178">18</offsets></xref><offsets xml_i="9486" xml_f="9533" txt_i="4178" txt_f="4225"> an anti-inflammatory and antioxidative action,</offsets><xref rid="b19-dmso-8-147" ref-type="bibr"><offsets xml_i="9576" xml_f="9578" txt_i="4225" txt_f="4227">19</offsets></xref><offsets xml_i="9585" xml_f="9726" txt_i="4227" txt_f="4368"> an inhibitory effect on the depression of expression of insulin-like growth factor-1 and hypoxia-inducible factor-1 due to oxidative stress,</offsets><xref rid="b20-dmso-8-147" ref-type="bibr"><offsets xml_i="9769" xml_f="9771" txt_i="4368" txt_f="4370">20</offsets></xref><offsets xml_i="9778" xml_f="9807" txt_i="4370" txt_f="4399"> and an antibacterial action.</offsets><xref rid="b21-dmso-8-147" ref-type="bibr"><offsets xml_i="9850" xml_f="9852" txt_i="4399" txt_f="4401">21</offsets></xref></p><p><offsets xml_i="9866" xml_f="10044" txt_i="4402" txt_f="4580">Recently, the antiobesity effects of rosehip have been clarified by in vitro and in vivo studies. Ninomiya et al showed that an 80% aqueous acetone extract of the whole fruit of </offsets><italic><offsets xml_i="10052" xml_f="10061" txt_i="4580" txt_f="4589">R. canina</offsets></italic><offsets xml_i="10070" xml_f="10212" txt_i="4589" txt_f="4731"> L. significantly suppressed body weight gain and prevented increases in the visceral fat in nonobese mice without any changes in diet intake.</offsets><xref rid="b3-dmso-8-147" ref-type="bibr"><offsets xml_i="10254" xml_f="10255" txt_i="4731" txt_f="4732">3</offsets></xref><offsets xml_i="10262" xml_f="10544" txt_i="4732" txt_f="5014"> They also reported that tiliroside upregulated the expression of peroxisome proliferator-activated receptor α messenger RNA in the liver. We showed that an aqueous ethanol extract of rosehip inhibited lipid accumulation in adipocytes using 3T3-L1 cells and diet-induced obese mice.</offsets><xref rid="b22-dmso-8-147" ref-type="bibr"><offsets xml_i="10587" xml_f="10589" txt_i="5014" txt_f="5016">22</offsets></xref><offsets xml_i="10596" xml_f="10727" txt_i="5016" txt_f="5147"> Andersson et al reported that rosehip juice decreased the systolic blood pressure and plasma cholesterol levels in obese subjects.</offsets><xref rid="b23-dmso-8-147" ref-type="bibr"><offsets xml_i="10770" xml_f="10772" txt_i="5147" txt_f="5149">23</offsets></xref><offsets xml_i="10779" xml_f="10858" txt_i="5149" txt_f="5228"> However, no clinical trials have evaluated the antiobesity effects of rosehip.</offsets></p><p><offsets xml_i="10865" xml_f="10967" txt_i="5229" txt_f="5331">Obesity is defined by the World Health Organization classification as a body mass index (BMI) ≥30 kg/m</offsets><sup><offsets xml_i="10972" xml_f="10973" txt_i="5331" txt_f="5332">2</offsets></sup><offsets xml_i="10979" xml_f="11015" txt_i="5332" txt_f="5368">, where a person with a BMI ≥25 kg/m</offsets><sup><offsets xml_i="11020" xml_f="11021" txt_i="5368" txt_f="5369">2</offsets></sup><offsets xml_i="11027" xml_f="11043" txt_i="5369" txt_f="5382"> but &lt;30 kg/m</offsets><sup><offsets xml_i="11048" xml_f="11049" txt_i="5382" txt_f="5383">2</offsets></sup><offsets xml_i="11055" xml_f="11082" txt_i="5383" txt_f="5410"> is classified as preobese.</offsets><xref rid="b24-dmso-8-147" ref-type="bibr"><offsets xml_i="11125" xml_f="11127" txt_i="5410" txt_f="5412">24</offsets></xref><offsets xml_i="11134" xml_f="11295" txt_i="5412" txt_f="5573"> In addition, based on the diagnostic criteria for obesity provided by the Japan Society for the Study of Obesity in 2011, an abdominal visceral fat area $100 cm</offsets><sup><offsets xml_i="11300" xml_f="11301" txt_i="5573" txt_f="5574">2</offsets></sup><offsets xml_i="11307" xml_f="11370" txt_i="5574" txt_f="5637"> is an important factor in obesity-related metabolic disorders.</offsets><xref rid="b25-dmso-8-147" ref-type="bibr"><offsets xml_i="11413" xml_f="11415" txt_i="5637" txt_f="5639">25</offsets></xref><offsets xml_i="11422" xml_f="11628" txt_i="5639" txt_f="5845"> In the present study, we targeted preobese subjects and confirmed the antiobesity effects of rosehip extract, where a reduction in the abdominal body fat area and body fat percent were the primary outcome.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="11679" xml_f="11700" txt_i="5847" txt_f="5868">Materials and methods</offsets></title><sec sec-type="methods"><title><offsets xml_i="11739" xml_f="11751" txt_i="5869" txt_f="5881">Study design</offsets></title><p><offsets xml_i="11762" xml_f="12500" txt_i="5882" txt_f="6620">A single-center, double-blind, randomized, placebo-controlled study was designed to evaluate the efficacy of rosehip extract. All experiments conformed to the Helsinki Declaration (adopted in 1964 and amended in 2008) and were conducted under the control of the principal investigator. The study protocol and all related documents were approved by Miyawaki Orthopedics Clinic Institutional Review Board. Appropriate explanations were provided to the subjects for important factors including the study purpose, contents, methods, and predicted adverse reactions. Informed consent was voluntarily obtained from each subject in writing. The study was performed in Fukuhara Clinic in Eniwa, Hokkaido, Japan, from August 2011 to December 2011.</offsets></p></sec><sec sec-type="subjects"><title><offsets xml_i="12542" xml_f="12550" txt_i="6622" txt_f="6630">Subjects</offsets></title><p><offsets xml_i="12561" xml_f="12882" txt_i="6631" txt_f="6952">In total, 152 subjects agreed to participate in the study, who were paid volunteers enrolled by the New Drug Research Center Inc. (Previously known as: New Drug Development Research Center Inc.), and 32 subjects (16 males and 16 females) who met the following inclusion and exclusion criteria were selected by screening (</offsets><xref ref-type="fig" rid="f1-dmso-8-147"><offsets xml_i="12923" xml_f="12931" txt_i="6952" txt_f="6960">Figure 1</offsets></xref><offsets xml_i="12938" xml_f="12940" txt_i="6960" txt_f="6962">, </offsets><xref ref-type="table" rid="t1-dmso-8-147"><offsets xml_i="12983" xml_f="12990" txt_i="6962" txt_f="6969">Table 1</offsets></xref><offsets xml_i="12997" xml_f="13109" txt_i="6969" txt_f="7081">). The 32 subjects were assigned to two equal groups to avoid bias related to sex, BMI, and body fat percentage.</offsets></p></sec><sec sec-type="materials"><title><offsets xml_i="13152" xml_f="13161" txt_i="7083" txt_f="7092">Materials</offsets></title><p><offsets xml_i="13172" xml_f="13622" txt_i="7093" txt_f="7543">Rosehip extract (Rosehip Polyphenol EX™, Morishita Jintan Co, Ltd, Osaka, Japan) comprised an aqueous ethanol extract of rosehip containing its seeds, dextrin, and cyclodextrin. This extract contains not less than 0.1% of tiliroside. The rosehip tablet contained 100 mg of rosehip extract and excipients, and the placebo tablet was indistinguishable from the rosehip tablet. The compositions and nutritional contents of both the tablets are shown in </offsets><xref ref-type="table" rid="t2-dmso-8-147"><offsets xml_i="13665" xml_f="13672" txt_i="7543" txt_f="7550">Table 2</offsets></xref><offsets xml_i="13679" xml_f="13680" txt_i="7550" txt_f="7551">.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="13721" xml_f="13752" txt_i="7553" txt_f="7584">Study schedule and measurements</offsets></title><p><offsets xml_i="13763" xml_f="15470" txt_i="7585" txt_f="9292">All subjects received one rosehip or placebo tablet once a day for 12 weeks by chewing, and they visited the clinic for assessments and measurements at the start of intake (W0) and on the 4th (W4), 8th (W8), and 12th week (W12). The subjects were allowed to drink only water after 9 pm on the day before the visit for examinations. During the study period, the subjects were not permitted to use medical products or foods with lipid-lowering or body fat-reducing actions, and we instructed the subjects not to change their life patterns greatly compared with that before the initiation of the study. All subjects were assessed to determine their physical parameters (body weight, body fat percentage, BMI, body temperature, blood pressure, and heart rate), hematological parameters (white blood cells, red blood cells, hemoglobin, hematocrit, and platelets), blood biochemical parameters (total protein [TP], albumin, albumin/globulin ratio, aspartate aminotransferase, alanine aminotransferase, γ-glutamyl transpeptidase, fasting blood sugar, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, uric acid, urea nitrogen, creatinine, Na, K, Cl, and Ca), urinalysis (urine protein, urine glucose, urobilinogen, bilirubin, ketone body, occult blood, specific gravity, and pH), and abdominal visceral and subcutaneous fat areas. All biochemical analyses were performed in Daiichi Kishimoto Clinical Laboratory Co, Ltd (Hokkaido, Japan) using the automatic analyzers XE-2100 (Sysmex Corp, Hyogo, Japan) for hematological analysis, JCA-BM8060 (JEOL Ltd, Tokyo, Japan) for blood biochemical analysis, and AX-4280 (Arkray, Inc., Kyoto, Japan) for urinalysis.</offsets></p></sec><sec><title><offsets xml_i="15492" xml_f="15528" txt_i="9294" txt_f="9330">Dietary record and physical activity</offsets></title><p><offsets xml_i="15539" xml_f="15840" txt_i="9331" txt_f="9632">To determine the energy intake and consumption, we collected meal survey slips where the subjects described their food content and the number of steps counted by a pedometer for 3 days prior to each visit at W0, W8, and W12, and we analyzed the data according to the procedure described by Maki et al.</offsets><xref rid="b26-dmso-8-147" ref-type="bibr"><offsets xml_i="15883" xml_f="15885" txt_i="9632" txt_f="9634">26</offsets></xref><offsets xml_i="15892" xml_f="16696" txt_i="9634" txt_f="10438"> Based on the meal records, a nutritionist calculated the energy intake and the amount of carbohydrates, fat, and proteins consumed. The energy consumption was calculated as the sum of the basal metabolic rate and kinetic energy. The basal metabolism is usually calculated as the “basal metabolism standard value × body weight”, but in this study, because the basal metabolism becomes excessive in obese subjects, it was calculated using the ideal body weight based on the height. Further, based on the assumption that the kinetic energy was 3.3 metabolic equivalents for males and 3.0 metabolic equivalents for females, the energy consumption (kcal) was calculated by multiplying the walking time from the number of steps by the kinetic energy (metabolic equivalents), body weight, and 1.05 (kcal/kg/h).</offsets><xref rid="b27-dmso-8-147" ref-type="bibr"><offsets xml_i="16739" xml_f="16741" txt_i="10438" txt_f="10440">27</offsets></xref></p></sec><sec><title><offsets xml_i="16770" xml_f="16789" txt_i="10442" txt_f="10461">Physical assessment</offsets></title><p><offsets xml_i="16800" xml_f="16894" txt_i="10462" txt_f="10556">Body weight was measured using the normal method, and BMI was calculated as body weight/height</offsets><xref rid="b2-dmso-8-147" ref-type="bibr"><offsets xml_i="16936" xml_f="16937" txt_i="10556" txt_f="10557">2</offsets></xref><offsets xml_i="16944" xml_f="17567" txt_i="10557" txt_f="11180">. Body fat percentages were determined using body composition analyzer (TBF-310, Tanita Corp, Tokyo, Japan). Computed tomography (CT) scans were performed using a CT-W450 CT scanner system (Hitachi Medical, Tokyo, Japan). Abdominal body fat areas (subcutaneous and visceral fat areas) were calculated based on an abdominal CT scan image using visceral fat measurement software (Fat Scan™ Ver. 3.0, N2 Systems Inc., Osaka, Japan). The total fat area was calculated as the sum of the subcutaneous and visceral fat areas. To consider the risk of radiation exposure in subjects, CT scans were performed only on W0, W8, and W12.</offsets></p></sec><sec><title><offsets xml_i="17589" xml_f="17606" txt_i="11182" txt_f="11199">Safety assessment</offsets></title><p><offsets xml_i="17617" xml_f="18068" txt_i="11200" txt_f="11651">The subjects entered their subjective symptoms in a subject diary. At W0, W4, W8, and W12, the investigator conducted a medical interview with the subjects based on the subject diary and the health status of the subjects was examined by auscultation and percussion. Body temperature, blood pressure, and pulse were measured at W0, W4, W8, and W12, and hematology tests, blood biochemical examinations, and urinalysis were performed at W0, W8, and W12.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="18109" xml_f="18129" txt_i="11653" txt_f="11673">Statistical analysis</offsets></title><p><offsets xml_i="18140" xml_f="18231" txt_i="11674" txt_f="11765">Mean values and standard deviations of each datum were calculated for each group. A paired </offsets><italic><offsets xml_i="18239" xml_f="18240" txt_i="11765" txt_f="11766">t</offsets></italic><offsets xml_i="18249" xml_f="18432" txt_i="11766" txt_f="11949">-test was used to compare the data before and after the intake within a group. The confirmation of homoscedasticity between the placebo and the rosehip groups was conducted using the </offsets><italic><offsets xml_i="18440" xml_f="18441" txt_i="11949" txt_f="11950">F</offsets></italic><offsets xml_i="18450" xml_f="18507" txt_i="11950" txt_f="12007">-test. If the homoscedasticity was verified, a Student’s </offsets><italic><offsets xml_i="18515" xml_f="18516" txt_i="12007" txt_f="12008">t</offsets></italic><offsets xml_i="18525" xml_f="18557" txt_i="12008" txt_f="12040">-test was used, whereas Welch’s </offsets><italic><offsets xml_i="18565" xml_f="18566" txt_i="12040" txt_f="12041">t</offsets></italic><offsets xml_i="18575" xml_f="18873" txt_i="12041" txt_f="12339">-test was used for comparisons if the variances were unequal. In addition, a signed rank sum test was used for intergroup comparisons of the semiquantitative urine values before and after the intake, and Wilcoxon’s rank sum test was used for comparisons between the placebo and test food groups. A </offsets><italic><offsets xml_i="18881" xml_f="18882" txt_i="12339" txt_f="12340">P</offsets></italic><offsets xml_i="18891" xml_f="19001" txt_i="12340" txt_f="12450"> value less than 5% was considered to be significant. Statistical analysis was performed using Microsoft Excel</offsets><sup><offsets xml_i="19006" xml_f="19007" txt_i="12450" txt_f="12451">®</offsets></sup><offsets xml_i="19013" xml_f="19061" txt_i="12451" txt_f="12499"> 2003 (Microsoft Corp, Redmond, WA, USA) and SAS</offsets><sup><offsets xml_i="19066" xml_f="19067" txt_i="12499" txt_f="12500">®</offsets></sup><offsets xml_i="19073" xml_f="19122" txt_i="12500" txt_f="12549"> 9.1.3 Foundation (SAS Institute, Cary, NC, USA).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="19169" xml_f="19176" txt_i="12552" txt_f="12559">Results</offsets></title><p><offsets xml_i="19187" xml_f="19451" txt_i="12560" txt_f="12824">The test food intake rates for the placebo group and the rose-hip group at 12 weeks were 99.5% and 99.6%, respectively. No subject left during the study period, and no outliers were observed for any parameter. Thus, all data were subjected to statistical analysis.</offsets></p><p><xref ref-type="table" rid="t3-dmso-8-147"><offsets xml_i="19501" xml_f="19508" txt_i="12825" txt_f="12832">Table 3</offsets></xref><offsets xml_i="19515" xml_f="19771" txt_i="12832" txt_f="13088"> shows the background data for the subjects. The abdominal total fat and abdominal visceral fat areas were somewhat higher in the control food group compared with the test food group; however, no significant difference was observed between the two groups (</offsets><italic><offsets xml_i="19779" xml_f="19780" txt_i="13088" txt_f="13089">P</offsets></italic><offsets xml_i="19789" xml_f="19832" txt_i="13089" txt_f="13132">=0.32 for the abdominal total fat area and </offsets><italic><offsets xml_i="19840" xml_f="19841" txt_i="13132" txt_f="13133">P</offsets></italic><offsets xml_i="19850" xml_f="20001" txt_i="13133" txt_f="13284">=0.21 in the abdominal visceral fat area). In addition, there were no significant differences between the two groups in terms of the other parameters. </offsets><xref ref-type="table" rid="t4-dmso-8-147"><offsets xml_i="20044" xml_f="20051" txt_i="13284" txt_f="13291">Table 4</offsets></xref><offsets xml_i="20058" xml_f="20372" txt_i="13291" txt_f="13605"> represents the energy intake and consumption, which was calculated based on the number of steps counted and the basal metabolism. No significant intragroup and intergroup differences were observed; thus, there were unlikely to have been any major changes in the lifestyles of the subjects during the study period.</offsets></p><p><offsets xml_i="20379" xml_f="20474" txt_i="13606" txt_f="13701">The results of the physical assessment of the placebo group and the rosehip group are shown in </offsets><xref ref-type="table" rid="t5-dmso-8-147"><offsets xml_i="20517" xml_f="20524" txt_i="13701" txt_f="13708">Table 5</offsets></xref><offsets xml_i="20531" xml_f="21746" txt_i="13708" txt_f="14923">. The measurement values at W12 were compared with those at W0, which showed significant decreases in the body weight and BMI in the rosehip group; the decreases in the body weight and BMI were significantly larger at W12 in the rosehip group than in the placebo group. Moreover, at W12, the body fat percentage was lower in the rosehip group compared with that in W0, but the difference was not significant. At W8 and W12, the abdominal visceral fat area in the rosehip group significantly decreased compared with the area at W0, and the decrease in the area at W12 was significantly larger than that in the placebo group. However, at W12, the abdominal total fat area in the rosehip group was significantly lower than that at W0, where the decrease was significantly larger than that in the placebo group. In contrast, there was no significant intragroup variation in the abdominal subcutaneous fat area, but the decrease in this area in the rosehip group at W12 was significantly larger than that in the placebo group. Further, blood pressure was measured using an automated sphygmomanometer, and pulse rates were measured at the same time as the blood pressure. The results of the measurement are also shown in </offsets><xref ref-type="table" rid="t5-dmso-8-147"><offsets xml_i="21789" xml_f="21796" txt_i="14923" txt_f="14930">Table 5</offsets></xref><offsets xml_i="21803" xml_f="21804" txt_i="14930" txt_f="14931">.</offsets></p><p><offsets xml_i="21811" xml_f="21996" txt_i="14932" txt_f="15117">The blood biochemical parameters, hepatic functional markers, fasting blood sugar, and serum lipids, which are cardiovascular disease risk factors, and other parameters, were measured (</offsets><xref ref-type="table" rid="t6-dmso-8-147"><offsets xml_i="22039" xml_f="22046" txt_i="15117" txt_f="15124">Table 6</offsets></xref><offsets xml_i="22053" xml_f="22283" txt_i="15124" txt_f="15354">). In the rosehip group, TP (W8), fasting blood sugar (W8), high-density lipoprotein cholesterol (W12), and systolic blood pressure (W4) changed significantly from W0, but the variations were within the normal physiological range.</offsets></p><p><offsets xml_i="22290" xml_f="23013" txt_i="15355" txt_f="16078">In the rosehip group, the following adverse events were recorded: common cold in four cases, headache in four cases, pyrexia and cough in two cases each, and sore throat, congested nose, loss of appetite, and abdominal pain in one case each. Furthermore, the adverse events observed in the placebo group were common cold in five cases, headache in three cases, pyrexia/cough in one case, and abdominal pain in one case. All these events were transient, and there was no observed aggravation due to the continuous intake of the placebo and the rosehip tablet in each group. There were no clinically problematic abnormalities or findings according to the physical assessments, blood biochemical and hematological parameters (</offsets><xref ref-type="table" rid="t7-dmso-8-147"><offsets xml_i="23056" xml_f="23063" txt_i="16078" txt_f="16085">Table 7</offsets></xref><offsets xml_i="23070" xml_f="23085" txt_i="16085" txt_f="16100">), urinalysis (</offsets><xref ref-type="table" rid="t8-dmso-8-147"><offsets xml_i="23128" xml_f="23135" txt_i="16100" txt_f="16107">Table 8</offsets></xref><offsets xml_i="23142" xml_f="23235" txt_i="16107" txt_f="16200">), and the medical interview by the investigator, which included auscultation and percussion.</offsets></p></sec><sec sec-type="discussion"><title><offsets xml_i="23279" xml_f="23289" txt_i="16202" txt_f="16212">Discussion</offsets></title><p><offsets xml_i="23300" xml_f="23502" txt_i="16213" txt_f="16415">The World Health Organization published diagnostic criteria for a syndrome called “metabolic syndrome” in 1998, and there have been extensive subsequent discussions/reviews on these diagnostic criteria.</offsets><xref rid="b28-dmso-8-147" ref-type="bibr"><offsets xml_i="23545" xml_f="23547" txt_i="16415" txt_f="16417">28</offsets></xref><offsets xml_i="23554" xml_f="23886" txt_i="16417" txt_f="16749"> Metabolic syndrome is a state that combines the risk factors of high blood sugar, high blood pressure, and hyperlipidemia due to visceral fat type obesity (visceral fat obesity/abdominal obesity). Study groups in various countries have reported that the cardiovascular disease risk is increased in subjects with metabolic syndrome.</offsets><xref rid="b29-dmso-8-147" ref-type="bibr"><offsets xml_i="23929" xml_f="23931" txt_i="16749" txt_f="16751">29</offsets></xref><offsets xml_i="23938" xml_f="23939" txt_i="16751" txt_f="16752">–</offsets><xref rid="b31-dmso-8-147" ref-type="bibr"><offsets xml_i="23982" xml_f="23984" txt_i="16752" txt_f="16754">31</offsets></xref></p><p><offsets xml_i="23998" xml_f="24264" txt_i="16755" txt_f="17021">Frequent attempts have been made to lower the risk of cardiovascular diseases by decreasing visceral fat in studies of obese subjects. The “VACATION-J study” of Japanese subjects showed that an increase in visceral fat heightened the risk of cardiovascular diseases.</offsets><xref rid="b32-dmso-8-147" ref-type="bibr"><offsets xml_i="24307" xml_f="24309" txt_i="17021" txt_f="17023">32</offsets></xref><offsets xml_i="24316" xml_f="24625" txt_i="17023" txt_f="17332"> In addition, a direct correlation was reported between decreased visceral fat and improvement in cardiovascular disease risk factors, including high blood pressure, hypo-high-density lipoprotein cholesterolemia, hyper-low-density lipoprotein cholesterolemia, hypertrig-lyceridemia, and fasting hyperglycemia.</offsets><xref rid="b33-dmso-8-147" ref-type="bibr"><offsets xml_i="24668" xml_f="24670" txt_i="17332" txt_f="17334">33</offsets></xref><offsets xml_i="24677" xml_f="24799" txt_i="17334" txt_f="17456"> Czernichow et al reported that abdominal obesity rather than BMI is related to death risk due to cardiovascular diseases.</offsets><xref rid="b34-dmso-8-147" ref-type="bibr"><offsets xml_i="24842" xml_f="24844" txt_i="17456" txt_f="17458">34</offsets></xref><offsets xml_i="24851" xml_f="24955" txt_i="17458" txt_f="17562"> Matsushita et al conducted a study of 6,292 Japanese subjects (5,606 males with a mean BMI of 24.1 kg/m</offsets><sup><offsets xml_i="24960" xml_f="24961" txt_i="17562" txt_f="17563">2</offsets></sup><offsets xml_i="24967" xml_f="25012" txt_i="17563" txt_f="17608"> and 686 females with a mean BMI of 23.0 kg/m</offsets><sup><offsets xml_i="25017" xml_f="25018" txt_i="17608" txt_f="17609">2</offsets></sup><offsets xml_i="25024" xml_f="25184" txt_i="17609" txt_f="17769">), which confirms that the abdominal visceral fat area is a better index of metabolic syndrome than the abdominal subcutaneous fat area and waist circumference.</offsets><xref rid="b35-dmso-8-147" ref-type="bibr"><offsets xml_i="25227" xml_f="25229" txt_i="17769" txt_f="17771">35</offsets></xref></p><p><offsets xml_i="25243" xml_f="25540" txt_i="17772" txt_f="18069">In an analysis of the effects of rosehip on cardiovascular disease risk factors, Andersson et al showed that a rosehip supplement suppressed the progression of diabetes in C57BL/6J mice and that downregulation of the lipogenic program in the liver was one of the mechanisms related to this effect.</offsets><xref rid="b36-dmso-8-147" ref-type="bibr"><offsets xml_i="25583" xml_f="25585" txt_i="18069" txt_f="18071">36</offsets></xref><offsets xml_i="25592" xml_f="25802" txt_i="18071" txt_f="18281"> They also examined the effects of rosehip juice on cardiovascular disease risk markers for type 2 diabetes and circulatory diseases using a randomized, double-blind, crossover method with obese human subjects.</offsets><xref rid="b23-dmso-8-147" ref-type="bibr"><offsets xml_i="25845" xml_f="25847" txt_i="18281" txt_f="18283">23</offsets></xref></p><p><offsets xml_i="25861" xml_f="26117" txt_i="18284" txt_f="18540">Based on the reports described earlier, we planned and conducted a clinical study to determine the antiobesity effects of rosehip extract. Obtained results suggest that rosehip extract could lead to weight loss, reducing the risk of cardiovascular disease.</offsets></p><p><offsets xml_i="26124" xml_f="26507" txt_i="18541" txt_f="18924">The rosehip extract used in this study is commercially available as a functional food ingredient named “Rosehip Polyphenol EX”, which includes ≥0.1% tiliroside as an active component. Prior to starting the study, we confirmed that tiliroside content in the rosehip extract was 0.12%. We showed that an aqueous ethanol extract of rosehip inhibits lipid accumulation in the adipocytes.</offsets><xref rid="b22-dmso-8-147" ref-type="bibr"><offsets xml_i="26550" xml_f="26552" txt_i="18924" txt_f="18926">22</offsets></xref><offsets xml_i="26559" xml_f="26875" txt_i="18926" txt_f="19242"> In addition, Ninomiya et al administered 0.1–10 mg/kg of tiliroside to mice for 2 weeks and observed the suppression of body weight gain, decreased amount of visceral fat, and they also found that peroxisome proliferator–activated receptor messenger RNA was upregulated in the liver of tiliroside-administered mice.</offsets><xref rid="b3-dmso-8-147" ref-type="bibr"><offsets xml_i="26917" xml_f="26918" txt_i="19242" txt_f="19243">3</offsets></xref><offsets xml_i="26925" xml_f="27032" txt_i="19243" txt_f="19350"> Furthermore, Goto et al demonstrated that tiliroside stimulates fatty acid oxidation in obesity model KK-A</offsets><sup><offsets xml_i="27037" xml_f="27038" txt_i="19350" txt_f="19351">y</offsets></sup><offsets xml_i="27044" xml_f="27050" txt_i="19351" txt_f="19357"> mice.</offsets><xref rid="b37-dmso-8-147" ref-type="bibr"><offsets xml_i="27093" xml_f="27095" txt_i="19357" txt_f="19359">37</offsets></xref><offsets xml_i="27102" xml_f="27521" txt_i="19359" txt_f="19778"> These reports indicate that the antiobesity effects of rosehip extract or tiliroside depend on the inhibition of lipid accumulation in adipose tissue and the stimulation of fatty acid oxidation. The rosehip tablet used in this study contained 0.1 mg of tiliroside in one tablet. Thus, we expect that tiliroside contributed to the reduction of visceral fat by the rosehip extract, and its effective dose seems very low.</offsets></p><p><offsets xml_i="27528" xml_f="27674" txt_i="19779" txt_f="19925">The autonomic nervous system (ANS) participates in the regulation of energy metabolism, and it plays an important role in body weight maintenance.</offsets><xref rid="b38-dmso-8-147" ref-type="bibr"><offsets xml_i="27717" xml_f="27719" txt_i="19925" txt_f="19927">38</offsets></xref><offsets xml_i="27726" xml_f="27727" txt_i="19927" txt_f="19928">,</offsets><xref rid="b39-dmso-8-147" ref-type="bibr"><offsets xml_i="27770" xml_f="27772" txt_i="19928" txt_f="19930">39</offsets></xref><offsets xml_i="27779" xml_f="27878" txt_i="19930" txt_f="20029"> ANS activity can be quantified based on the power spectral analysis of the heart rate variability.</offsets><xref rid="b40-dmso-8-147" ref-type="bibr"><offsets xml_i="27921" xml_f="27923" txt_i="20029" txt_f="20031">40</offsets></xref><offsets xml_i="27930" xml_f="27931" txt_i="20031" txt_f="20032">,</offsets><xref rid="b41-dmso-8-147" ref-type="bibr"><offsets xml_i="27974" xml_f="27976" txt_i="20032" txt_f="20034">41</offsets></xref><offsets xml_i="27983" xml_f="28365" txt_i="20034" txt_f="20416"> A preliminary study showed that the rosehip extract stimulates ANS activity and tends to increase the fat utilization at rest and during exercise based on power spectral analysis of the heart rate variability and an analysis of expired gas in 25 healthy male and female adults. In addition, the visceral fat is more reactive than the subcutaneous fat to lipolysis by catecholamine.</offsets><xref rid="b42-dmso-8-147" ref-type="bibr"><offsets xml_i="28408" xml_f="28410" txt_i="20416" txt_f="20418">42</offsets></xref><offsets xml_i="28417" xml_f="28418" txt_i="20418" txt_f="20419">,</offsets><xref rid="b43-dmso-8-147" ref-type="bibr"><offsets xml_i="28461" xml_f="28463" txt_i="20419" txt_f="20421">43</offsets></xref><offsets xml_i="28470" xml_f="28730" txt_i="20421" txt_f="20681"> In the present study, the abdominal visceral fat area was reduced earlier than the subcutaneous fat area. Hence, it is possible that the fat combustion effect induced by enhanced ANS activity is involved in the body fat-lowering effect of the rosehip extract.</offsets></p><p><offsets xml_i="28737" xml_f="29133" txt_i="20682" txt_f="21078">It is well known that the body weight and body fat mass are affected by the daily diet and exercise regimens. Thus, we monitored the energy intake and consumption of the subjects, but there were no major changes in the lifestyles of the subjects during the study period. Therefore, the changes detected in the present study were attributable to the rosehip extract, rather than lifestyle changes.</offsets></p><p><offsets xml_i="29140" xml_f="29797" txt_i="21079" txt_f="21736">The safety of rosehip extract has already been demonstrated by a single-dose toxicity test, a 30-day repeated-dose toxicity test, and an Ames test (unpublished data). In this study, the results of the safety outcomes, subjective symptoms, and medical assessments demonstrated that no serious adverse events were caused by the test food during the study period. Furthermore, rosehip extract does not interact with nifedipine, a cytochrome P450 3A substrate, according to a pharmacokinetics study in rats (unpublished data). However, a previous study reported that rosehip fruit juice delayed the peak time required to attain the maximum blood concentration (</offsets><italic><offsets xml_i="29805" xml_f="29806" txt_i="21736" txt_f="21737">T</offsets></italic><sub><offsets xml_i="29820" xml_f="29823" txt_i="21737" txt_f="21740">max</offsets></sub><offsets xml_i="29829" xml_f="29930" txt_i="21740" txt_f="21841">) and there was a 16% decrease in the area under the blood concentration–time curve with paracetamol.</offsets><xref rid="b44-dmso-8-147" ref-type="bibr"><offsets xml_i="29973" xml_f="29975" txt_i="21841" txt_f="21843">44</offsets></xref><offsets xml_i="29982" xml_f="30127" txt_i="21843" txt_f="21988"> Thus, the rosehip extract is generally recognized as safe, but care should be taken when patients who are receiving medication also use rosehip.</offsets></p><p><offsets xml_i="30134" xml_f="30404" txt_i="21989" txt_f="22259">In conclusion, the results of the present study demonstrate that rosehip extract may be useful as a supplement to safely reduce abdominal visceral fat in preobese subjects. Therefore, it is anticipated that rosehip extract will reduce the risk of cardiovascular disease.</offsets></p></sec></body><back><fn-group><fn><p><bold>Disclosure</bold></p><p>A Nagatomo, N Nishida and Y Matsuura are employees of Morishita Jintan Co, Ltd, and were not involved in the data analysis. A Noro, Y Kozai, and H Sato are employees of New Drug Research Center, Inc. I Fukuhara is a principal investigator of this clinical study.</p></fn></fn-group><ref-list><title>References</title><ref id="b1-dmso-8-147"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spiegelman</surname><given-names>BM</given-names></name><name><surname>Flier</surname><given-names>JS</given-names></name></person-group><article-title>Obesity and the regulation of energy balance</article-title><source>Cell</source><year>2001</year><volume>104</volume><fpage>531</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">11239410</pub-id></element-citation></ref><ref id="b2-dmso-8-147"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crowley</surname><given-names>VE</given-names></name></person-group><article-title>Overview of human obesity and central mechanisms regulating energy homeostasis</article-title><source>Ann Clin Biochem</source><year>2008</year><volume>45</volume><fpage>245</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">18482911</pub-id></element-citation></ref><ref id="b3-dmso-8-147"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ninomiya</surname><given-names>K</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Kubo</surname><given-names>M</given-names></name><name><surname>Morikawa</surname><given-names>T</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Yohikawa</surname><given-names>M</given-names></name></person-group><article-title><italic>Rosa canina</italic>: structural requirements and mode of action of <italic>trans</italic>-tiliroside</article-title><source>Bioorg Med Chem Lett</source><year>2007</year><volume>17</volume><fpage>3059</fpage><lpage>3064</lpage><pub-id pub-id-type="pmid">17400451</pub-id></element-citation></ref><ref id="b4-dmso-8-147"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>M</given-names></name></person-group><article-title>Rosehip – an evidence based herbal medicine for inflammation and arthritis</article-title><source>Aust Fam Physician</source><year>2012</year><volume>41</volume><fpage>495</fpage><lpage>498</lpage><pub-id pub-id-type="pmid">22762068</pub-id></element-citation></ref><ref id="b5-dmso-8-147"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rein</surname><given-names>E</given-names></name><name><surname>Kharazmi</surname><given-names>A</given-names></name><name><surname>Winther</surname><given-names>K</given-names></name></person-group><article-title>A herbal remedy, Hyben Vital (stand. powder of a subspecies of <italic>Rosa canina</italic> fruits), reduces pain and improves general wellbeing in patients with osteoarthritis – a double-blind, placebo-controlled, randomised trial</article-title><source>Phytomedicine</source><year>2004</year><volume>11</volume><fpage>383</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">15330493</pub-id></element-citation></ref><ref id="b6-dmso-8-147"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willich</surname><given-names>SN</given-names></name><name><surname>Rossnagel</surname><given-names>K</given-names></name><name><surname>Roll</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Rose hip herbal remedy in patients with rheumatoid arthritis – a randomised controlled trial</article-title><source>Phytomedicine</source><year>2010</year><volume>17</volume><fpage>87</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">19818588</pub-id></element-citation></ref><ref id="b7-dmso-8-147"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chrubasik</surname><given-names>C</given-names></name><name><surname>Roufogalis</surname><given-names>BD</given-names></name><name><surname>Müller-Ladner</surname><given-names>U</given-names></name><name><surname>Chrubasik</surname><given-names>S</given-names></name></person-group><article-title>A systematic review on the <italic>Rosa canina</italic> effect and efficacy profiles</article-title><source>Phytother Res</source><year>2008</year><volume>22</volume><fpage>725</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">18384191</pub-id></element-citation></ref><ref id="b8-dmso-8-147"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Björk</surname><given-names>L</given-names></name><name><surname>Trajkovski</surname><given-names>V</given-names></name><name><surname>Uggla</surname><given-names>M</given-names></name></person-group><article-title>Evaluation of antioxidant activities of rosehip ethanol extracts in different test systems</article-title><source>J Sci Food Agric</source><year>2000</year><volume>80</volume><fpage>2021</fpage><lpage>2027</lpage></element-citation></ref><ref id="b9-dmso-8-147"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lattanzio</surname><given-names>F</given-names></name><name><surname>Greco</surname><given-names>E</given-names></name><name><surname>Carretta</surname><given-names>D</given-names></name><name><surname>Cervellati</surname><given-names>R</given-names></name><name><surname>Govoni</surname><given-names>P</given-names></name><name><surname>Speroni</surname><given-names>E</given-names></name></person-group><article-title><italic>In vivo</italic> anti-inflammatory effect of <italic>Rosa canina</italic> L. extract</article-title><source>J Ethnopharmacol</source><year>2011</year><volume>137</volume><fpage>880</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">21771653</pub-id></element-citation></ref><ref id="b10-dmso-8-147"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jäger</surname><given-names>AK</given-names></name><name><surname>Petersen</surname><given-names>KN</given-names></name><name><surname>Thomasen</surname><given-names>G</given-names></name><name><surname>Christensen</surname><given-names>SB</given-names></name></person-group><article-title>Isolation of linoleic and α-linolenic acids as COX-1 and -2 inhibitors in rose hip</article-title><source>Phytother Res</source><year>2008</year><volume>22</volume><fpage>982</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">18389471</pub-id></element-citation></ref><ref id="b11-dmso-8-147"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olsson</surname><given-names>ME</given-names></name><name><surname>Gustavsson</surname><given-names>KE</given-names></name><name><surname>Andersson</surname><given-names>S</given-names></name><name><surname>Nilsson</surname><given-names>A</given-names></name><name><surname>Duan</surname><given-names>RD</given-names></name></person-group><article-title>Inhibition of cancer cell proliferation <italic>in vitro</italic> by fruit and berry extracts and correlations with antioxidant levels</article-title><source>J Agric Food Chem</source><year>2004</year><volume>52</volume><fpage>7264</fpage><lpage>7271</lpage><pub-id pub-id-type="pmid">15563205</pub-id></element-citation></ref><ref id="b12-dmso-8-147"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tayefi-Nasrabadi</surname><given-names>H</given-names></name><name><surname>Sadigh-Eteghad</surname><given-names>S</given-names></name><name><surname>Aghdam</surname><given-names>Z</given-names></name></person-group><article-title>The effects of the hydroalcohol extract of <italic>Rosa canina</italic> L. fruit on experimentally nephrolithiasic Wistar rats</article-title><source>Phytother Res</source><year>2012</year><volume>26</volume><fpage>78</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">21544885</pub-id></element-citation></ref><ref id="b13-dmso-8-147"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>M</given-names></name></person-group><article-title>Inhibitory effect of quercetin isolated from rose hip (<italic>Rosa canina</italic> L.) against melanogenesis by mouse melanoma cells</article-title><source>Biosci Biotechnol Biochem</source><year>2009</year><volume>73</volume><fpage>1989</fpage><lpage>1993</lpage><pub-id pub-id-type="pmid">19734679</pub-id></element-citation></ref><ref id="b14-dmso-8-147"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mandade</surname><given-names>RJ</given-names></name><name><surname>Choudhury</surname><given-names>A</given-names></name><name><surname>Harsulkar</surname><given-names>A</given-names></name><name><surname>Wakade</surname><given-names>R</given-names></name></person-group><article-title>Role of the <italic>Rosa canina</italic> L. leaf extract as an antidiarrheal drug in rodents</article-title><source>Indian J Pharmacol</source><year>2011</year><volume>43</volume><fpage>316</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">21713098</pub-id></element-citation></ref><ref id="b15-dmso-8-147"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winther</surname><given-names>K</given-names></name><name><surname>Apel</surname><given-names>K</given-names></name><name><surname>Thamsborg</surname><given-names>G</given-names></name></person-group><article-title>A powder made from seeds and shells of a rose-hip subspecies (<italic>Rosa canina</italic>) reduces symptoms of knee and hip osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial</article-title><source>Scand J Rheumatol</source><year>2005</year><volume>34</volume><fpage>302</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">16195164</pub-id></element-citation></ref><ref id="b16-dmso-8-147"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>I</given-names></name><name><surname>Stănilă</surname><given-names>A</given-names></name><name><surname>Stănilă</surname><given-names>S</given-names></name></person-group><article-title>Bioactive compounds and antioxidant activity of <italic>Rosa canina</italic> L. biotypes from spontaneous flora of Transylvania</article-title><source>Chem Cent J</source><year>2013</year><volume>7</volume><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">23618509</pub-id></element-citation></ref><ref id="b17-dmso-8-147"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>KY</given-names></name><name><surname>Oh</surname><given-names>SR</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><etal></etal></person-group><article-title>Anti-complement activity of tiliroside from the flower buds of <italic>Magnolia fargesii</italic></article-title><source>Biol Pharm Bull</source><year>1998</year><volume>21</volume><fpage>1077</fpage><lpage>1078</lpage><pub-id pub-id-type="pmid">9821813</pub-id></element-citation></ref><ref id="b18-dmso-8-147"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuda</surname><given-names>H</given-names></name><name><surname>Ninomiya</surname><given-names>K</given-names></name><name><surname>Shimoda</surname><given-names>H</given-names></name><name><surname>Yoshikawa</surname><given-names>M</given-names></name></person-group><article-title>Hepatoprotective principles from the flowers of <italic>Tilia argentea</italic> (Linden): structure requirements of tiliroside and mechanisms of action</article-title><source>Bioorg Med Chem</source><year>2002</year><volume>10</volume><fpage>707</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">11814859</pub-id></element-citation></ref><ref id="b19-dmso-8-147"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname><given-names>A</given-names></name><name><surname>Recio</surname><given-names>MC</given-names></name><name><surname>Schinella</surname><given-names>GR</given-names></name><etal></etal></person-group><article-title>Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside</article-title><source>Eur J Pharmacol</source><year>2003</year><volume>461</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">12568916</pub-id></element-citation></ref><ref id="b20-dmso-8-147"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomczyk</surname><given-names>M</given-names></name><name><surname>Tumanov</surname><given-names>A</given-names></name><name><surname>Zaniewska</surname><given-names>A</given-names></name><name><surname>Surazynski</surname><given-names>A</given-names></name></person-group><article-title>The potential mechanism of tiliroside-dependent inhibition of t-butylhydroperoxide-induced oxidative stress in endometrial carcinoma cells</article-title><source>Planta Med</source><year>2010</year><volume>76</volume><fpage>963</fpage><lpage>968</lpage><pub-id pub-id-type="pmid">20186656</pub-id></element-citation></ref><ref id="b21-dmso-8-147"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumarasamy</surname><given-names>Y</given-names></name><name><surname>Cox</surname><given-names>PJ</given-names></name><name><surname>Jaspars</surname><given-names>M</given-names></name><name><surname>Rashid</surname><given-names>MA</given-names></name><name><surname>Sarker</surname><given-names>SD</given-names></name></person-group><article-title>Bioactive flavonoid glycosides from the seeds of <italic>Rosa canina</italic></article-title><source>Pharm Biol</source><year>2003</year><volume>41</volume><fpage>237</fpage><lpage>242</lpage></element-citation></ref><ref id="b22-dmso-8-147"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagatomo</surname><given-names>A</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Matsuura</surname><given-names>Y</given-names></name><name><surname>Shibata</surname><given-names>N</given-names></name></person-group><article-title>Rosehip extract inhibits lipid accumulation in white adipose tissue by suppressing the expression of peroxisome proliferator-activated receptor gamma</article-title><source>Prev Nutr Food Sci</source><year>2013</year><volume>18</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">24471115</pub-id></element-citation></ref><ref id="b23-dmso-8-147"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Berger</surname><given-names>K</given-names></name><name><surname>Högberg</surname><given-names>A</given-names></name><name><surname>Landin-Olsson</surname><given-names>M</given-names></name><name><surname>Holm</surname><given-names>C</given-names></name></person-group><article-title>Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons</article-title><source>Eur J Clin Nutr</source><year>2012</year><volume>66</volume><fpage>585</fpage><lpage>590</lpage><pub-id pub-id-type="pmid">22166897</pub-id></element-citation></ref><ref id="b24-dmso-8-147"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO</collab></person-group><article-title>Obesity: preventing and managing the global epidemic. Report of a WHO consultation</article-title><source>World Health Organ Tech Rep Ser</source><year>2000</year><volume>894</volume><fpage>i</fpage><lpage>xii</lpage><fpage>1</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">11234459</pub-id></element-citation></ref><ref id="b25-dmso-8-147"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name></person-group><article-title>Characteristics and significance of criteria for obesity disease in Japan 2011</article-title><source>Nihon Rinsho</source><year>2013</year><volume>71</volume><fpage>257</fpage><lpage>261</lpage><comment>Japanese</comment><pub-id pub-id-type="pmid">23631202</pub-id></element-citation></ref><ref id="b26-dmso-8-147"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maki</surname><given-names>KC</given-names></name><name><surname>Reeves</surname><given-names>MS</given-names></name><name><surname>Farmer</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults</article-title><source>J Nutr</source><year>2009</year><volume>139</volume><fpage>264</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">19074207</pub-id></element-citation></ref><ref id="b27-dmso-8-147"><label>27</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Ministry of Health, Labour and Welfare</collab></person-group><source>Exercise and Physical Activity References for Health Promotion 2006 (EPAR2006): Physical Activity, Exercise, and Physical Fitness</source><publisher-loc>Tokyo, Japan</publisher-loc><publisher-name>Ministry of Health, Labour and Welfare</publisher-name><year>2006</year><comment>Japanese</comment></element-citation></ref><ref id="b28-dmso-8-147"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><article-title>Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation</article-title><source>Diabet Med</source><year>1998</year><volume>15</volume><fpage>539</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">9686693</pub-id></element-citation></ref><ref id="b29-dmso-8-147"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuzawa</surname><given-names>Y</given-names></name></person-group><article-title>The metabolic syndrome and adipocytokines</article-title><source>FEBS Lett</source><year>2006</year><volume>580</volume><fpage>2917</fpage><lpage>2921</lpage><pub-id pub-id-type="pmid">16674947</pub-id></element-citation></ref><ref id="b30-dmso-8-147"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakka</surname><given-names>HM</given-names></name><name><surname>Laaksonen</surname><given-names>DE</given-names></name><name><surname>Lakka</surname><given-names>TA</given-names></name><etal></etal></person-group><article-title>The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2709</fpage><lpage>2716</lpage><pub-id pub-id-type="pmid">12460094</pub-id></element-citation></ref><ref id="b31-dmso-8-147"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isomaa</surname><given-names>B</given-names></name><name><surname>Almgren</surname><given-names>P</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Cardiovascular morbidity and mortality associated with the metabolic syndrome</article-title><source>Diabetes Care</source><year>2001</year><volume>24</volume><fpage>683</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">11315831</pub-id></element-citation></ref><ref id="b32-dmso-8-147"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiuge-Shimizu</surname><given-names>A</given-names></name><name><surname>Kishida</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Reduction of visceral fat correlates with the decrease in the number of obesity-related cardiovascular risk factors in Japanese with Abdominal Obesity (VACATION-J Study)</article-title><source>J Atheroscler Thromb</source><year>2012</year><volume>19</volume><fpage>1006</fpage><lpage>1018</lpage><pub-id pub-id-type="pmid">22785136</pub-id></element-citation></ref><ref id="b33-dmso-8-147"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hiuge-Shimizu</surname><given-names>A</given-names></name><name><surname>Kishida</surname><given-names>K</given-names></name><name><surname>Funahashi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Coexistence of visceral fat and multiple risk factor accumulations is strongly associated with coronary artery disease in Japanese (the VACATION-J Study)</article-title><source>J Atheroscler Thromb</source><year>2012</year><volume>19</volume><fpage>657</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">22472215</pub-id></element-citation></ref><ref id="b34-dmso-8-147"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Czernichow</surname><given-names>S</given-names></name><name><surname>Kengne</surname><given-names>AP</given-names></name><name><surname>Stamatakis</surname><given-names>E</given-names></name><name><surname>Hamer</surname><given-names>M</given-names></name><name><surname>Batty</surname><given-names>GD</given-names></name></person-group><article-title>Body mass index, waist circumference and waist-hip ratio: which is the better discriminator of cardiovascular disease mortality risk? Evidence from an individual-participant meta-analysis of 82 864 participants from nine cohort studies</article-title><source>Obes Rev</source><year>2011</year><volume>12</volume><fpage>680</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">21521449</pub-id></element-citation></ref><ref id="b35-dmso-8-147"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsushita</surname><given-names>Y</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals: the Hitachi Health Study</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>2117</fpage><lpage>2119</lpage><pub-id pub-id-type="pmid">20460443</pub-id></element-citation></ref><ref id="b36-dmso-8-147"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>U</given-names></name><name><surname>Henriksson</surname><given-names>E</given-names></name><name><surname>Ström</surname><given-names>K</given-names></name><name><surname>Alenfall</surname><given-names>J</given-names></name><name><surname>Göransson</surname><given-names>O</given-names></name><name><surname>Holm</surname><given-names>C</given-names></name></person-group><article-title>Rose hip exerts antidiabetic effects via a mechanism involving down-regulation of the hepatic lipogenic program</article-title><source>Am J Physiol Endocrinol Metab</source><year>2011</year><volume>300</volume><issue>1</issue><fpage>E111</fpage><lpage>E121</lpage><pub-id pub-id-type="pmid">20959531</pub-id></element-citation></ref><ref id="b37-dmso-8-147"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Teraminami</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><etal></etal></person-group><article-title>Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice</article-title><source>J Nutr Biochem</source><year>2012</year><volume>23</volume><fpage>768</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">21889885</pub-id></element-citation></ref><ref id="b38-dmso-8-147"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenard</surname><given-names>NR</given-names></name><name><surname>Berthoud</surname><given-names>HR</given-names></name></person-group><article-title>Central and peripheral regulation of food intake and physical activity: pathways and genes</article-title><source>Obesity (Silver Spring)</source><year>2008</year><volume>16</volume><fpage>S11</fpage><lpage>S22</lpage><pub-id pub-id-type="pmid">19190620</pub-id></element-citation></ref><ref id="b39-dmso-8-147"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalsbeek</surname><given-names>A</given-names></name><name><surname>Bruinstroop</surname><given-names>E</given-names></name><name><surname>Yi</surname><given-names>CX</given-names></name><name><surname>Klieverik</surname><given-names>LP</given-names></name><name><surname>La Fleur</surname><given-names>SE</given-names></name><name><surname>Fliers</surname><given-names>E</given-names></name></person-group><article-title>Hypothalamic control of energy metabolism via autonomic nervous system</article-title><source>Ann N Y Acad Sci</source><year>2010</year><volume>1212</volume><fpage>114</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">21070249</pub-id></element-citation></ref><ref id="b40-dmso-8-147"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akselrod</surname><given-names>S</given-names></name><name><surname>Gordon</surname><given-names>D</given-names></name><name><surname>Ubel</surname><given-names>FA</given-names></name><name><surname>Shannon</surname><given-names>DC</given-names></name><name><surname>Berger</surname><given-names>AC</given-names></name><name><surname>Cohen</surname><given-names>RJ</given-names></name></person-group><article-title>Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-by-beat cardiovascular control</article-title><source>Science</source><year>1981</year><volume>213</volume><fpage>220</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">6166045</pub-id></element-citation></ref><ref id="b41-dmso-8-147"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moritani</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>T</given-names></name><name><surname>Shinohara</surname><given-names>M</given-names></name><name><surname>Mimasa</surname><given-names>F</given-names></name><name><surname>Shibata</surname><given-names>M</given-names></name></person-group><article-title>Comparison of sympatho-vagal function among diabetic patients, normal controls and endurance athletes by heart rate spectral analysis</article-title><source>J Sports Med Sci</source><year>1993</year><volume>7</volume><fpage>31</fpage><lpage>39</lpage></element-citation></ref><ref id="b42-dmso-8-147"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hellmér</surname><given-names>J</given-names></name><name><surname>Marcus</surname><given-names>C</given-names></name><name><surname>Sonnenfeld</surname><given-names>T</given-names></name><name><surname>Arner</surname><given-names>P</given-names></name></person-group><article-title>Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells</article-title><source>J Clin Endocrinol Metab</source><year>1992</year><volume>75</volume><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">1320047</pub-id></element-citation></ref><ref id="b43-dmso-8-147"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>C</given-names></name><name><surname>Tsujita</surname><given-names>T</given-names></name><name><surname>Okuda</surname><given-names>H</given-names></name></person-group><article-title>Norepinephrine-induced lipolysis in rat fat cells from visceral and subcutaneous sites: role of hormone-sensitive lipase and lipid droplets</article-title><source>J Lipid Res</source><year>1997</year><volume>38</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">9034207</pub-id></element-citation></ref><ref id="b44-dmso-8-147"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Åkerman</surname><given-names>U</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Influence of fruit drinks with or without lactobacillus Lp299v on the gastrointestinal uptake of paracetamol in man</article-title><source>BMC Res Notes</source><year>2009</year><volume>2</volume><fpage>45</fpage><pub-id pub-id-type="pmid">19298683</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-dmso-8-147" position="float"><label>Figure 1</label><caption><p>Flow diagram through the phases of the study.</p></caption><graphic xlink:href="dmso-8-147Fig1"></graphic></fig><table-wrap id="t1-dmso-8-147" position="float"><label>Table 1</label><caption><p>Inclusion and exclusion criteria for the selection of study participants</p></caption><table frame="hsides" rules="groups"><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Inclusion criteria</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI: ≥ 25.0 kg/m<sup>2</sup>, and &lt;30.0 kg/m<sup>2</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Sufficient understanding of the study purpose and methods, and predicted adverse reactions</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Voluntarily agreed to participate in the study in writing</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Exclusion criteria</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">History of drug allergy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Excessive smoking habit, alcohol addiction, and markedly irregular eating habits</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Significant impediment of liver function or renal function</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Surgical history of the gastrointestinal tract region including gastric resection, gastro-enterorrhaphy, and intestinal resection</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Donated 400 mL blood within 12 weeks before the intake of the test food, 200 mL blood within 4 weeks before the intake of the test food, or donated blood components (donation of plasma components and thrombocyte components) within 2 weeks before the intake of the test food</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Works until late in the evening and irregular shift workers</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pregnant women or women who are nursing or planning for pregnancy within 6 months</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Judged as ineligible to participate in the study by an investigator</td></tr></tbody></table><table-wrap-foot><fn id="tfn1-dmso-8-147"><p><bold>Abbreviation:</bold> BMI, body mass index.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-dmso-8-147" position="float"><label>Table 2</label><caption><p>Composition and nutritional content of test foods</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"></th><th colspan="2" valign="top" align="left" rowspan="1">Serving size: 1 tablet (1,500 mg)
<hr></hr></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">Placebo</th><th valign="top" align="left" rowspan="1" colspan="1">Rosehip</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Composition</bold></td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rosehip extract (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">0.0</td><td valign="top" align="left" rowspan="1" colspan="1">100.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Maltitol (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">933.0</td><td valign="top" align="left" rowspan="1" colspan="1">833.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dextrin (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">150.0</td><td valign="top" align="left" rowspan="1" colspan="1">150.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Crystalline cellulose (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">135.0</td><td valign="top" align="left" rowspan="1" colspan="1">135.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Citric acid (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">100.0</td><td valign="top" align="left" rowspan="1" colspan="1">100.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lemon juice (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">50.0</td><td valign="top" align="left" rowspan="1" colspan="1">50.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lemon flavoring (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">30.0</td><td valign="top" align="left" rowspan="1" colspan="1">30.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Others (mg)</td><td valign="top" align="left" rowspan="1" colspan="1">102.0</td><td valign="top" align="left" rowspan="1" colspan="1">102.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Nutritional content</bold></td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Energy (kcal)</td><td valign="top" align="left" rowspan="1" colspan="1">4.35</td><td valign="top" align="left" rowspan="1" colspan="1">4.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Protein (g)</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Carbohydrate (g)</td><td valign="top" align="left" rowspan="1" colspan="1">1.361</td><td valign="top" align="left" rowspan="1" colspan="1">1.353</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fat (g)</td><td valign="top" align="left" rowspan="1" colspan="1">0.077</td><td valign="top" align="left" rowspan="1" colspan="1">0.081</td></tr></tbody></table></table-wrap><table-wrap id="t3-dmso-8-147" position="float"><label>Table 3</label><caption><p>Characteristics of the subjects at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">Placebo group (n=16)</th><th valign="top" align="left" rowspan="1" colspan="1">Rosehip group (n=16)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (year)</td><td valign="top" align="left" rowspan="1" colspan="1">50.6±13.7</td><td valign="top" align="left" rowspan="1" colspan="1">50.1±9.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Height (cm)</td><td valign="top" align="left" rowspan="1" colspan="1">161.51±7.84</td><td valign="top" align="left" rowspan="1" colspan="1">161.81±7.62</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body weight (kg)</td><td valign="top" align="left" rowspan="1" colspan="1">70.01±8.36</td><td valign="top" align="left" rowspan="1" colspan="1">70.31±6.19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body fat percent (%)</td><td valign="top" align="left" rowspan="1" colspan="1">31.34±4.93</td><td valign="top" align="left" rowspan="1" colspan="1">30.56±6.96</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">26.78±1.53</td><td valign="top" align="left" rowspan="1" colspan="1">26.84±1.37</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Abdominal fat area (cm<sup>2</sup>)</bold></td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total</td><td valign="top" align="left" rowspan="1" colspan="1">305.35±59.45</td><td valign="top" align="left" rowspan="1" colspan="1">286.61±44.46</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Subcutaneous</td><td valign="top" align="left" rowspan="1" colspan="1">200.39±61.95</td><td valign="top" align="left" rowspan="1" colspan="1">197.94±56.45</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Visceral</td><td valign="top" align="left" rowspan="1" colspan="1">104.96±34.24</td><td valign="top" align="left" rowspan="1" colspan="1">88.67±36.96</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SBP (mm-Hg)</td><td valign="top" align="left" rowspan="1" colspan="1">132.28±17.75</td><td valign="top" align="left" rowspan="1" colspan="1">137.03±20.08</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DBP (mm-Hg)</td><td valign="top" align="left" rowspan="1" colspan="1">80.84±9.89</td><td valign="top" align="left" rowspan="1" colspan="1">83.91±14.29</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FBS (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">88.7±10.7</td><td valign="top" align="left" rowspan="1" colspan="1">83.9±7.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Cho (mg/dL)</bold></td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total-Cho</td><td valign="top" align="left" rowspan="1" colspan="1">205.1±25.7</td><td valign="top" align="left" rowspan="1" colspan="1">210.1±25.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-Cho</td><td valign="top" align="left" rowspan="1" colspan="1">60.3±11.6</td><td valign="top" align="left" rowspan="1" colspan="1">55.8±9.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL-Cho</td><td valign="top" align="left" rowspan="1" colspan="1">126.8±23.6</td><td valign="top" align="left" rowspan="1" colspan="1">137.4±21.8</td></tr></tbody></table><table-wrap-foot><fn id="tfn2-dmso-8-147"><p><bold>Notes:</bold> Values represent the mean ± SD. There were no significant differences between the groups.</p></fn><fn id="tfn3-dmso-8-147"><p><bold>Abbreviations:</bold> BMI, body mass index; Cho, cholesterol; DBP, diastolic blood pressure; FBS, fasting blood sugar; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4-dmso-8-147" position="float"><label>Table 4</label><caption><p>Changes in energy intake and energy consumption after the daily intake of placebo or rosehip</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">W0</th><th valign="top" align="left" rowspan="1" colspan="1">W8</th><th valign="top" align="left" rowspan="1" colspan="1">W12</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Energy intake (kcal)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">2,098.78±480.92</td><td valign="top" align="left" rowspan="1" colspan="1">1,920.00±499.58</td><td valign="top" align="left" rowspan="1" colspan="1">1,953.31±409.77</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">1,954.73±386.26</td><td valign="top" align="left" rowspan="1" colspan="1">1,881.11±458.54</td><td valign="top" align="left" rowspan="1" colspan="1">1,856.84±354.58</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Energy consumption (kcal)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">1,480.57±188.14</td><td valign="top" align="left" rowspan="1" colspan="1">1,516.07±199.13</td><td valign="top" align="left" rowspan="1" colspan="1">1,497.07±209.55</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">1,501.12±152.12</td><td valign="top" align="left" rowspan="1" colspan="1">1,490.68±175.76</td><td valign="top" align="left" rowspan="1" colspan="1">1,498.37±155.34</td></tr></tbody></table><table-wrap-foot><fn id="tfn4-dmso-8-147"><p><bold>Notes:</bold> Values represent the mean ± SD. There were no significant differences between the groups. Energy intake was calculated based on the meal survey slips. Energy consumption was calculated by multiplying kinetic energy (the walking time calculated from the number of steps), body weight, and coefficient (1.05).</p></fn><fn id="tfn5-dmso-8-147"><p><bold>Abbreviations:</bold> SD, standard deviation; W0, start of the intake; W8, 8th week; W12, 12th week.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5-dmso-8-147" position="float"><label>Table 5</label><caption><p>Changes in physical assessment parameters after the daily intake of placebo or rosehip</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">W0</th><th valign="top" align="left" rowspan="1" colspan="1">W4</th><th valign="top" align="left" rowspan="1" colspan="1">W8</th><th valign="top" align="left" rowspan="1" colspan="1">W12</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Body weight (kg)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">70.01±8.36</td><td valign="top" align="left" rowspan="1" colspan="1">70.75±8.01<sup>#</sup> (0.74±1.05<sup>#</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">70.50±7.82 (0.49±1.11)</td><td valign="top" align="left" rowspan="1" colspan="1">69.75±8.30 (−0.26±1.34)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">70.31±6.19</td><td valign="top" align="left" rowspan="1" colspan="1">70.33±6.25 (0.01±0.83*)</td><td valign="top" align="left" rowspan="1" colspan="1">69.71±6.43 (−0.60±1.21*)</td><td valign="top" align="left" rowspan="1" colspan="1">68.91±6.51<sup>##</sup> (−1.40±1.52<sup>*,##</sup>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Body fat percentage (%)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">31.34±4.93</td><td valign="top" align="left" rowspan="1" colspan="1">31.15±5.15 (−0.19±1.65)</td><td valign="top" align="left" rowspan="1" colspan="1">30.92±5.28 (−0.42±2.00)</td><td valign="top" align="left" rowspan="1" colspan="1">31.08±5.40 (−0.26±1.54)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">30.56±6.96</td><td valign="top" align="left" rowspan="1" colspan="1">30.48±6.86 (−0.08±1.68)</td><td valign="top" align="left" rowspan="1" colspan="1">30.29±7.17 (−0.28±2.44)</td><td valign="top" align="left" rowspan="1" colspan="1">29.56±6.16 (−1.00±1.88)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">26.78±1.53</td><td valign="top" align="left" rowspan="1" colspan="1">27.06±1.38<sup>#</sup> (0.28±0.41<sup>#</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">26.97±1.36 (0.19±0.42)</td><td valign="top" align="left" rowspan="1" colspan="1">26.68±1.55 (−0.10±0.51)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">26.84±1.37</td><td valign="top" align="left" rowspan="1" colspan="1">26.84±1.39 (0.01±0.32*)</td><td valign="top" align="left" rowspan="1" colspan="1">26.62±1.45 (−0.22±0.47*)</td><td valign="top" align="left" rowspan="1" colspan="1">26.30±1.52<sup>##</sup> (−0.54±0.59<sup>*,##</sup>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal total fat area (cm<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">305.35±59.45</td><td valign="top" align="left" rowspan="1" colspan="1">Not measured</td><td valign="top" align="left" rowspan="1" colspan="1">304.15±60.79 (−1.20±11.84)</td><td valign="top" align="left" rowspan="1" colspan="1">307.44±60.73 (2.09±15.51)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">286.61±44.46</td><td valign="top" align="left" rowspan="1" colspan="1">Not measured</td><td valign="top" align="left" rowspan="1" colspan="1">279.73±51.68 (−6.88±17.85)</td><td valign="top" align="left" rowspan="1" colspan="1">268.13±55.78<sup>##</sup> (−18.48±23.02<sup>**,##</sup>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal subcutaneous fat area (cm<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">200.39±61.95</td><td valign="top" align="left" rowspan="1" colspan="1">Not measured</td><td valign="top" align="left" rowspan="1" colspan="1">199.52±61.30 (−0.87±8.99)</td><td valign="top" align="left" rowspan="1" colspan="1">203.64±62.25 (3.24±13.42)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">197.94±56.45</td><td valign="top" align="left" rowspan="1" colspan="1">Not measured</td><td valign="top" align="left" rowspan="1" colspan="1">197.05±57.65 (−0.89±15.76)</td><td valign="top" align="left" rowspan="1" colspan="1">188.72±53.72 (−9.23±17.70<sup>*</sup>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abdominal visceral fat area (cm<sup>2</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">104.96±34.24</td><td valign="top" align="left" rowspan="1" colspan="1">Not measured</td><td valign="top" align="left" rowspan="1" colspan="1">104.63±37.64 (−0.33±10.05)</td><td valign="top" align="left" rowspan="1" colspan="1">103.81±32.21 (−1.15±10.15)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">88.67±36.96</td><td valign="top" align="left" rowspan="1" colspan="1">Not measured</td><td valign="top" align="left" rowspan="1" colspan="1">82.68±37.05<sup>##</sup> (−5.99±5.55<sup>##</sup>)</td><td valign="top" align="left" rowspan="1" colspan="1">79.41±34.92<sup>*,##</sup> (−9.26±10.72<sup>*,##</sup>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">SBP (mm Hg)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">132.28±17.75</td><td valign="top" align="left" rowspan="1" colspan="1">129.63±16.48</td><td valign="top" align="left" rowspan="1" colspan="1">131.66±18.04</td><td valign="top" align="left" rowspan="1" colspan="1">129.53±17.31</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">137.03±20.08</td><td valign="top" align="left" rowspan="1" colspan="1">129.25±17.05<sup>#</sup></td><td valign="top" align="left" rowspan="1" colspan="1">132.44±15.54</td><td valign="top" align="left" rowspan="1" colspan="1">133.28±13.03</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DBP (mm Hg)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">80.84±9.89</td><td valign="top" align="left" rowspan="1" colspan="1">78.69±11.14</td><td valign="top" align="left" rowspan="1" colspan="1">79.69±11.09</td><td valign="top" align="left" rowspan="1" colspan="1">78.88±12.39</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">83.91±14.29</td><td valign="top" align="left" rowspan="1" colspan="1">80.72±12.29</td><td valign="top" align="left" rowspan="1" colspan="1">81.09±12.89</td><td valign="top" align="left" rowspan="1" colspan="1">82.53±11.18</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HR (bpm)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">66.25±8.64</td><td valign="top" align="left" rowspan="1" colspan="1">67.69±9.86</td><td valign="top" align="left" rowspan="1" colspan="1">68.03±10.64</td><td valign="top" align="left" rowspan="1" colspan="1">67.75±10.43</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">65.03±9.23</td><td valign="top" align="left" rowspan="1" colspan="1">67.50±11.54</td><td valign="top" align="left" rowspan="1" colspan="1">66.34±9.43</td><td valign="top" align="left" rowspan="1" colspan="1">65.38±7.66</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-dmso-8-147"><p><bold>Notes:</bold> Values represent the mean ± SD. Figures in parentheses represent the changes from W0 for each group. There were significant differences between the groups according to the Student’s <italic>t</italic>-test or Welch’s <italic>t</italic>-test (*<italic>P</italic>&lt;0.05; **<italic>P</italic>&lt;0.01). In addition, there were significant differences from the W0 for each group according to the paired <italic>t</italic>-test (<sup>#</sup><italic>P</italic>&lt;0.05; <sup>##</sup><italic>P</italic>&lt;0.01).</p></fn><fn id="tfn7-dmso-8-147"><p><bold>Abbreviations:</bold> BMI, body mass index; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; SD, standard deviation; W0, start of the intake; W4, 4th week; W8, 8th week; W12, 12th week.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t6-dmso-8-147" position="float"><label>Table 6</label><caption><p>Changes in blood biochemical parameters after the daily intake of placebo or rosehip</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">Standard range</th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">W0</th><th valign="top" align="left" rowspan="1" colspan="1">W8</th><th valign="top" align="left" rowspan="1" colspan="1">W12</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">TP (g/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">6.5–8.2</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">7.19±0.25</td><td valign="top" align="left" rowspan="1" colspan="1">7.29±0.33</td><td valign="top" align="left" rowspan="1" colspan="1">7.23±0.24</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">7.18±0.31</td><td valign="top" align="left" rowspan="1" colspan="1">7.31±0.36<sup>#</sup></td><td valign="top" align="left" rowspan="1" colspan="1">7.19±0.33</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Albumin (g/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">3.7–5.5</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">4.26±0.24</td><td valign="top" align="left" rowspan="1" colspan="1">4.24±0.28</td><td valign="top" align="left" rowspan="1" colspan="1">4.19±0.31</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">4.34±0.17</td><td valign="top" align="left" rowspan="1" colspan="1">4.26±0.17</td><td valign="top" align="left" rowspan="1" colspan="1">4.26±0.19</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">A/G ratio</td><td valign="top" align="left" rowspan="1" colspan="1">1.30–2.00</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">1.464±0.161</td><td valign="top" align="left" rowspan="1" colspan="1">1.407±0.198<sup>#</sup></td><td valign="top" align="left" rowspan="1" colspan="1">1.389±0.189<sup>##</sup></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">1.551±0.232</td><td valign="top" align="left" rowspan="1" colspan="1">1.426±0.218<sup>##</sup></td><td valign="top" align="left" rowspan="1" colspan="1">1.478±0.217<sup>##</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">AST (U/L)</td><td valign="top" align="left" rowspan="1" colspan="1">10–40</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">20.6±3.9</td><td valign="top" align="left" rowspan="1" colspan="1">20.6±5.0</td><td valign="top" align="left" rowspan="1" colspan="1">20.4±4.8</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">20.4±4.0</td><td valign="top" align="left" rowspan="1" colspan="1">21.3±5.3</td><td valign="top" align="left" rowspan="1" colspan="1">21.2±4.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ALT (U/L)</td><td valign="top" align="left" rowspan="1" colspan="1">5–45</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">21.1±10.0</td><td valign="top" align="left" rowspan="1" colspan="1">21.1±11.0</td><td valign="top" align="left" rowspan="1" colspan="1">21.3±13.5</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">22.8±8.2</td><td valign="top" align="left" rowspan="1" colspan="1">22.2±9.2</td><td valign="top" align="left" rowspan="1" colspan="1">23.6±9.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">γ-GTP (U/L)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 79</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">39.4±21.9</td><td valign="top" align="left" rowspan="1" colspan="1">39.7±23.9</td><td valign="top" align="left" rowspan="1" colspan="1">39.1±24.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 48</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">28.9±27.7</td><td valign="top" align="left" rowspan="1" colspan="1">25.6±17.6</td><td valign="top" align="left" rowspan="1" colspan="1">24.4±16.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">FBS (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">70–109</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">88.7±10.7</td><td valign="top" align="left" rowspan="1" colspan="1">87.3±9.5</td><td valign="top" align="left" rowspan="1" colspan="1">88.9±7.9</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">83.9±7.7</td><td valign="top" align="left" rowspan="1" colspan="1">87.4±8.2<sup>##</sup></td><td valign="top" align="left" rowspan="1" colspan="1">86.5±8.5</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total-Cho (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">150–219</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">205.1±25.7</td><td valign="top" align="left" rowspan="1" colspan="1">205.2±24.7</td><td valign="top" align="left" rowspan="1" colspan="1">207.8±26.7</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">210.1±25.7</td><td valign="top" align="left" rowspan="1" colspan="1">209.6±25.7</td><td valign="top" align="left" rowspan="1" colspan="1">213.1±30.9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL-Cho (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 40–80</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">60.3±11.6</td><td valign="top" align="left" rowspan="1" colspan="1">57.3±11.0</td><td valign="top" align="left" rowspan="1" colspan="1">62.4±12.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 40–90</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">55.8±9.2</td><td valign="top" align="left" rowspan="1" colspan="1">56.8±9.8</td><td valign="top" align="left" rowspan="1" colspan="1">58.6±10.2<sup>##</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL-Cho (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">70–139</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">126.8±23.6</td><td valign="top" align="left" rowspan="1" colspan="1">127.1±22.3</td><td valign="top" align="left" rowspan="1" colspan="1">128.4±26.1</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">137.4±21.8</td><td valign="top" align="left" rowspan="1" colspan="1">132.8±21.7</td><td valign="top" align="left" rowspan="1" colspan="1">136.4±27.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TG (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">50–149</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">100.9±36.8</td><td valign="top" align="left" rowspan="1" colspan="1">106.3±31.9</td><td valign="top" align="left" rowspan="1" colspan="1">101.1±32.1</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">94.9±39.2</td><td valign="top" align="left" rowspan="1" colspan="1">101.7±38.8</td><td valign="top" align="left" rowspan="1" colspan="1">98.4±38.1</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Uric acid (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 3.6–7.0</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">5.26±1.11</td><td valign="top" align="left" rowspan="1" colspan="1">5.01±1.02</td><td valign="top" align="left" rowspan="1" colspan="1">5.18±0.92</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 2.7–7.0</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">5.21±1.12</td><td valign="top" align="left" rowspan="1" colspan="1">5.05±0.99</td><td valign="top" align="left" rowspan="1" colspan="1">5.09±1.20</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urea nitrogen (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">8–20</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">13.44±2.53</td><td valign="top" align="left" rowspan="1" colspan="1">12.88±2.40</td><td valign="top" align="left" rowspan="1" colspan="1">14.26±3.77</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">14.59±2.77</td><td valign="top" align="left" rowspan="1" colspan="1">14.40±3.64</td><td valign="top" align="left" rowspan="1" colspan="1">14.31±3.76</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Creatinine (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 0.65–1.09</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">0.693±0.120</td><td valign="top" align="left" rowspan="1" colspan="1">0.668±0.133</td><td valign="top" align="left" rowspan="1" colspan="1">0.674±0.102</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 0.46–0.82</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">0.649±0.158</td><td valign="top" align="left" rowspan="1" colspan="1">0.649±0.139</td><td valign="top" align="left" rowspan="1" colspan="1">0.649±0.155</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Na (mEq/L)</td><td valign="top" align="left" rowspan="1" colspan="1">135–145</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">140.0±1.0</td><td valign="top" align="left" rowspan="1" colspan="1">139.8±1.0</td><td valign="top" align="left" rowspan="1" colspan="1">140.1±1.6</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">140.7±1.1</td><td valign="top" align="left" rowspan="1" colspan="1">140.7±1.0<sup>*</sup></td><td valign="top" align="left" rowspan="1" colspan="1">140.8±1.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">K (mEq/L)</td><td valign="top" align="left" rowspan="1" colspan="1">3.5–5.0</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">4.23±0.22</td><td valign="top" align="left" rowspan="1" colspan="1">4.13±0.32</td><td valign="top" align="left" rowspan="1" colspan="1">4.16±0.35</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">4.12±0.36</td><td valign="top" align="left" rowspan="1" colspan="1">4.16±0.29</td><td valign="top" align="left" rowspan="1" colspan="1">4.09±0.21</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cl (mEq/L)</td><td valign="top" align="left" rowspan="1" colspan="1">98–108</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">102.6±1.6</td><td valign="top" align="left" rowspan="1" colspan="1">101.7±1.7<sup>#</sup></td><td valign="top" align="left" rowspan="1" colspan="1">102.5±2.0</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">103.4±1.9</td><td valign="top" align="left" rowspan="1" colspan="1">102.6±2.4</td><td valign="top" align="left" rowspan="1" colspan="1">103.1±1.7</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ca (mg/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">8.2–10.0</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">9.08±0.38</td><td valign="top" align="left" rowspan="1" colspan="1">8.79±0.45<sup>##</sup></td><td valign="top" align="left" rowspan="1" colspan="1">8.84±0.33<sup>##</sup></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">9.09±0.36</td><td valign="top" align="left" rowspan="1" colspan="1">8.89±0.34<sup>#</sup></td><td valign="top" align="left" rowspan="1" colspan="1">8.88±0.27<sup>##</sup></td></tr></tbody></table><table-wrap-foot><fn id="tfn8-dmso-8-147"><p><bold>Notes:</bold> Values represent the mean ± SD. There was significant difference between the groups according to the Student’s <italic>t</italic>-test (*<italic>P</italic>&lt;0.05). There were significant differences from W0 for each group according to the paired <italic>t</italic>-test (<sup>#</sup><italic>P</italic>&lt;0.05; <sup>##</sup><italic>P</italic>&lt;0.01).</p></fn><fn id="tfn9-dmso-8-147"><p><bold>Abbreviations:</bold> A/G, albumin/globulin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cho, cholesterol; F, female; FBS, fasting blood sugar; γ-GTP, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, male; SD, standard deviation; TG, triglyceride; TP, total protein; W0, start of the intake; W8, 8th week; W12, 12th week.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7-dmso-8-147" position="float"><label>Table 7</label><caption><p>Changes in hematological parameters after the daily intake of placebo or rosehip</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">Standard range</th><th valign="top" align="left" rowspan="1" colspan="1">Group</th><th valign="top" align="left" rowspan="1" colspan="1">W0</th><th valign="top" align="left" rowspan="1" colspan="1">W8</th><th valign="top" align="left" rowspan="1" colspan="1">W12</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">WBC (/μL)</td><td valign="top" align="left" rowspan="1" colspan="1">3,500–9,700</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">5,488±1,178</td><td valign="top" align="left" rowspan="1" colspan="1">5,939±1,255</td><td valign="top" align="left" rowspan="1" colspan="1">6,035±1,593</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">5,831±1,940</td><td valign="top" align="left" rowspan="1" colspan="1">5,443±1,664</td><td valign="top" align="left" rowspan="1" colspan="1">5,411±1,416</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RBC (×10<sup>4</sup>/μL)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 438–577</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">486.4±28.8</td><td valign="top" align="left" rowspan="1" colspan="1">488.1±27.3</td><td valign="top" align="left" rowspan="1" colspan="1">484.9±27.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 376–516</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">476.2±32.6</td><td valign="top" align="left" rowspan="1" colspan="1">476.4±31.0</td><td valign="top" align="left" rowspan="1" colspan="1">478.4±32.0</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hb (g/dL)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 13.6–18.3</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">14.76±1.13</td><td valign="top" align="left" rowspan="1" colspan="1">14.79±1.25</td><td valign="top" align="left" rowspan="1" colspan="1">14.66±1.11</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 11.2–15.2</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">14.45±1.14</td><td valign="top" align="left" rowspan="1" colspan="1">14.47±1.12</td><td valign="top" align="left" rowspan="1" colspan="1">14.38±1.15</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ht (%)</td><td valign="top" align="left" rowspan="1" colspan="1">M: 40.4–51.9</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">44.88±3.11</td><td valign="top" align="left" rowspan="1" colspan="1">45.19±3.10</td><td valign="top" align="left" rowspan="1" colspan="1">44.31±2.74<sup>#</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">F: 343–452</td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">43.87±2.73</td><td valign="top" align="left" rowspan="1" colspan="1">44.02±2.72</td><td valign="top" align="left" rowspan="1" colspan="1">43.79±2.90</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Plt (×10<sup>4</sup>/μL)</td><td valign="top" align="left" rowspan="1" colspan="1">14.0–37.9</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">23.90±5.28</td><td valign="top" align="left" rowspan="1" colspan="1">25.18±6.76</td><td valign="top" align="left" rowspan="1" colspan="1">24.45±5.67</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">23.23±5.34</td><td valign="top" align="left" rowspan="1" colspan="1">25.33±6.19<sup>##</sup></td><td valign="top" align="left" rowspan="1" colspan="1">23.53±4.87</td></tr></tbody></table><table-wrap-foot><fn id="tfn10-dmso-8-147"><p><bold>Notes:</bold> Values represent the mean ± SD. There were significant differences from W0 for each group according to the paired <italic>t</italic>-test (<sup>#</sup><italic>P</italic>&lt;0.05; <sup>##</sup><italic>P</italic>&lt;0.01).</p></fn><fn id="tfn11-dmso-8-147"><p><bold>Abbreviations:</bold> F, female; Hb, hemoglobin; Ht, hematocrit; M, male; Plt, platelets; RBC, red blood cells; SD, standard deviation; WBC, white blood cells; W0, start of the intake; W8, 8th week; W12, 12th week.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t8-dmso-8-147" position="float"><label>Table 8</label><caption><p>Changes in urinalysis parameters after the daily intake of placebo or rosehip</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"></th><th rowspan="2" valign="top" align="left" colspan="1">Standardrange</th><th rowspan="2" valign="top" align="left" colspan="1">Group</th><th colspan="5" valign="top" align="left" rowspan="1">W0
<hr></hr></th><th colspan="5" valign="top" align="left" rowspan="1">W8
<hr></hr></th><th colspan="5" valign="top" align="left" rowspan="1">W12
<hr></hr></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1">−</th><th valign="top" align="left" rowspan="1" colspan="1">±</th><th valign="top" align="left" rowspan="1" colspan="1">+</th><th colspan="2" valign="top" align="left" rowspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">−</th><th valign="top" align="left" rowspan="1" colspan="1">±</th><th valign="top" align="left" rowspan="1" colspan="1">+</th><th colspan="2" valign="top" align="left" rowspan="1"></th><th valign="top" align="left" rowspan="1" colspan="1">−</th><th valign="top" align="left" rowspan="1" colspan="1">±</th><th valign="top" align="left" rowspan="1" colspan="1">+</th><th colspan="2" valign="top" align="left" rowspan="1"></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Urine protein</td><td valign="top" align="left" rowspan="1" colspan="1">(−)–(±)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urine glucose</td><td valign="top" align="left" rowspan="1" colspan="1">(−)–(±)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Urobilinogen</td><td valign="top" align="left" rowspan="1" colspan="1">(±)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bilirubin</td><td valign="top" align="left" rowspan="1" colspan="1">(−)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Ketone body</td><td valign="top" align="left" rowspan="1" colspan="1">(−)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">16</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1"></td><td colspan="5" valign="top" align="left" rowspan="1">
<hr></hr></td><td colspan="5" valign="top" align="left" rowspan="1">
<hr></hr></td><td colspan="5" valign="top" align="left" rowspan="1">
<hr></hr></td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">−</td><td valign="top" align="left" rowspan="1" colspan="1">±</td><td valign="top" align="left" rowspan="1" colspan="1">+</td><td valign="top" align="left" rowspan="1" colspan="1"><bold>2+</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>3+</bold></td><td valign="top" align="left" rowspan="1" colspan="1">−</td><td valign="top" align="left" rowspan="1" colspan="1">±</td><td valign="top" align="left" rowspan="1" colspan="1">+</td><td valign="top" align="left" rowspan="1" colspan="1"><bold>2+</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>3+</bold></td><td valign="top" align="left" rowspan="1" colspan="1">−</td><td valign="top" align="left" rowspan="1" colspan="1">±</td><td valign="top" align="left" rowspan="1" colspan="1">+</td><td valign="top" align="left" rowspan="1" colspan="1"><bold>2+</bold></td><td valign="top" align="left" rowspan="1" colspan="1"><bold>3+</bold></td></tr><tr><td colspan="3" valign="top" align="left" rowspan="1"></td><td colspan="5" valign="top" align="left" rowspan="1">
<hr></hr></td><td colspan="5" valign="top" align="left" rowspan="1">
<hr></hr></td><td colspan="5" valign="top" align="left" rowspan="1">
<hr></hr></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Occult blood</td><td valign="top" align="left" rowspan="1" colspan="1">(−)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">14</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">15</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">13</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">1</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td colspan="18" valign="top" align="left" rowspan="1">
<hr></hr></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Specific gravity</td><td valign="top" align="left" rowspan="1" colspan="1">1.008–1.034</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">1.0161</td><td valign="top" align="left" rowspan="1" colspan="1">±0.0078</td><td colspan="3" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">1.0159±</td><td valign="top" align="left" rowspan="1" colspan="1">0.0086</td><td colspan="3" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">1.0149</td><td valign="top" align="left" rowspan="1" colspan="1">±0.0088</td><td colspan="3" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">1.0159</td><td valign="top" align="left" rowspan="1" colspan="1">±0.0063</td><td colspan="3" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">1.0171±</td><td valign="top" align="left" rowspan="1" colspan="1">0.0076</td><td colspan="3" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">1.0171</td><td valign="top" align="left" rowspan="1" colspan="1">±0.0062</td><td colspan="3" valign="top" align="left" rowspan="1"></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pH</td><td valign="top" align="left" rowspan="1" colspan="1">4.8–7.5</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">6.13±0.89</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">6.34±0.94</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">5.91±0.71</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr><tr><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">Rosehip</td><td valign="top" align="left" rowspan="1" colspan="1">6.13±0.72</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">6.41±0.93</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td colspan="2" valign="top" align="left" rowspan="1"></td><td valign="top" align="left" rowspan="1" colspan="1">6.28±0.88</td><td colspan="2" valign="top" align="left" rowspan="1"></td><td colspan="2" valign="top" align="left" rowspan="1"></td></tr></tbody></table><table-wrap-foot><fn id="tfn12-dmso-8-147"><p><bold>Notes:</bold> Urine protein, urine glucose, urobilinogen, bilirubin, ketone body, and occult blood: Values indicate the numbers of subjects. The symbols indicate the degree of each item: −, negative; ±, false-positive; +, positive (mild); 2+, positive (moderate); 3+, positive (serious). Specific gravity, pH: values represent the mean ± SD. There were no significant differences between the groups.</p></fn><fn id="tfn13-dmso-8-147"><p><bold>Abbreviations:</bold> SD, standard deviation; W0, start of the intake; W8, 8th week; W12, 12th week.</p></fn></table-wrap-foot></table-wrap></floats-group></article>